Cetuximab (Erbitux) — CPB 0684 | AETNA Coverage Update

Aetna modified CPB 0684 for cetuximab (Erbitux), effective December 5, 2025. Here's what billing teams need to know before submitting claims under this updated coverage policy.

Aetna, a CVS Health company, updated Clinical Policy Bulletin CPB 0684 governing cetuximab (Erbitux) coverage for commercial medical plans. The policy covers billing under HCPCS J9055 (injection, cetuximab, 10 mg) and ties approval to molecular testing codes CPT 81275 and 81276 for KRAS variant analysis. If your team bills cetuximab for colorectal, head and neck, NSCLC, penile, or squamous cell skin cancer patients, this policy change affects your prior authorization workflow and your medical necessity documentation requirements.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna (CVS Health)
Policy	Cetuximab (Erbitux) — CPB 0684
Policy Code	CPB 0684
Change Type	Modified
Effective Date	December 5, 2025
Impact Level	High
Specialties Affected	Medical Oncology, Hematology/Oncology, Head & Neck Surgery, Thoracic Oncology, Radiation Oncology
Key Action	Audit all active cetuximab prior authorizations against the updated criteria before submitting reauthorization requests

---

Aetna Cetuximab Coverage Criteria and Medical Necessity Requirements 2025

Aetna considers cetuximab medically necessary across five oncology indications — but each one carries specific molecular, staging, and combination-therapy requirements. Miss any single criterion and you're looking at a claim denial.

Precertification is required for all Aetna participating providers and members in applicable plan designs. Call (866) 752-7021 or fax (888) 267-3277. Do this before administration, not after.

Colorectal Cancer

This is the most complex indication in the policy. The member must have unresectable, inoperable, advanced, or metastatic colorectal cancer — including appendiceal adenocarcinoma and anal adenocarcinoma. They also must not have previously failed on panitumumab (J9303).

From there, approval runs down one of two tracks.

Track 1 — RAS wild-type disease:

#	Covered Indication Copy
1	RAS (KRAS and NRAS) mutation status must be negative (wild-type)
2	If the tumor tests BRAF V600E positive, cetuximab must be used in combination with encorafenib (Braftovi)
3	For first-line colon cancer treatment, the tumor must be left-sided only

Track 2 — KRAS G12C mutation positive:

#	Covered Indication Copy
1	Disease must carry KRAS G12C mutation
2	Cetuximab must be used in combination with sotorasib (Lumakras) or adagrasib (Krazati)
3	Member must have previously received chemotherapy

The left-sided tumor requirement for first-line colon cancer is a hard stop. If you're submitting for a right-sided tumor in the first-line setting, RAS wild-type status alone won't get approval. Document tumor sidedness explicitly in your prior authorization request.

RAS and NRAS molecular testing is itself considered medically necessary under this coverage policy for predicting non-response to cetuximab in colorectal cancer. CPT 81275 (KRAS gene analysis, exon 2 variants) and CPT 81276 (additional KRAS variants, e.g., codon 61, codon 146) are covered when selection criteria are met. Have those results in the chart before you submit.

Head and Neck Cancer

The criteria here are broader. Aetna covers cetuximab when any one of these is true:

#	Covered Indication Copy
1	Disease is locally or regionally advanced, unresectable, recurrent, persistent, or metastatic
2	Member is unfit for surgery
3	Cetuximab will be used in combination with radiation or chemotherapy

ICD-10 codes C00.0 through C14.8 cover the bulk of squamous cell carcinoma of the head and neck for this indication. Head and neck is the most straightforward approval path in this policy. Even so, document the specific staging and combination therapy intent clearly in your auth request.

Non-Small Cell Lung Cancer (NSCLC)

This indication is tightly constrained. Both criteria must be met:

#	Covered Indication Copy
1	Cetuximab must be used in combination with afatinib (Gilotrif)
2	The member must have a known sensitizing EGFR mutation — specifically EGFR exon 19 deletion, L858R mutation, EGFR S768I, L861Q, or G719X mutation — and must have experienced disease progression on prior EGFR tyrosine kinase inhibitor therapy

This is a subsequent-treatment indication only. You won't get approval for cetuximab in NSCLC as a first-line agent or without confirmed EGFR mutation documentation. Molecular pathology reports belong in the auth package.

There is no specific HCPCS code for afatinib in the policy — the companion drugs listed under the afatinib grouping (J8565 for gefitinib, J0640 for leucovorin) confirm the payer is tracking combination regimens, but afatinib itself requires documentation of the drug name in the clinical record.

Penile Cancer

Cetuximab is covered as a single agent for subsequent treatment of metastatic or recurrent penile cancer. This is one of the cleaner approvals in the policy — single agent, no combination requirement — but "subsequent treatment" means prior therapy must be documented.

Squamous Cell Skin Cancer

Coverage extends to unresectable, inoperable, incompletely resected, locally advanced, regional, recurrent, or distant metastatic squamous cell skin cancer. Cetuximab may be used as a single agent or in combination with carboplatin (J9045) and paclitaxel (J9267).

Continuation of Therapy

Aetna covers reauthorization when there is no evidence of unacceptable toxicity or disease progression on the current regimen. Reauthorization requests that don't document ongoing response — or that fail to address toxicity — will stall. Build a documentation checklist for your reauth workflow now.

---

Aetna Cetuximab Exclusions and Non-Covered Indications

Aetna considers all cetuximab indications outside the five listed above as experimental, investigational, or unproven. That's a broad exclusion. Off-label use outside these approved pathways won't get through precertification.

Some specific situations to flag:

If your oncology team is using cetuximab in a way that doesn't map to one of these five indications with their sub-criteria fully met, you're billing into a wall.

---

Coverage Indications at a Glance

---

Aetna Cetuximab Billing Guidelines and Action Items 2025

Copy Action Items

If you're managing a mixed oncology payer mix and you're not sure how this update applies to your specific patient population, loop in your compliance officer or billing consultant before the December 5, 2025 effective date.

---

CPT, HCPCS, and ICD-10 Codes for Cetuximab Under CPB 0684

Covered HCPCS Code (When Selection Criteria Are Met)

Code	Type	Description Copy
J9055	HCPCS	Injection, cetuximab, 10 mg

Covered CPT Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
81275	CPT	KRAS gene analysis; variants in exon 2
81276	CPT	KRAS gene analysis; additional variants (e.g., codon 61, codon 146)

Other CPT Codes Related to This Policy

Code	Type	Description Copy
88363	CPT	Examination and selection of retrieved archival tissue for molecular analysis
96401–96450	CPT	Chemotherapy administration (full range of administration codes)

Companion Drug HCPCS Codes Referenced in Policy

Key ICD-10-CM Diagnosis Codes

This policy references 434 total ICD-10-CM codes. The full code list is available at the Aetna CPB 0684 source document. Review your diagnosis coding against the complete list — especially for colorectal, head and neck, and NSCLC diagnoses — before submitting claims.

---